Bristol-Myers Squibb Company (BMY) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BMY Revenue Growth
Revenue Breakdown (FY 2025)
BMY's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
BMY Revenue Analysis (2014–2025)
As of May 6, 2026, Bristol-Myers Squibb Company (BMY) generated trailing twelve-month (TTM) revenue of $48.48 billion, reflecting modest growth of +2.6% year-over-year. The most recent quarter (Q1 2026) recorded $11.49 billion in revenue, down 8.1% sequentially.
Looking at the longer-term picture, BMY's 5-year compound annual growth rate (CAGR) stands at +2.5%, indicating moderate growth over time. The company achieved its highest annual revenue of $48.30 billion in 2024.
Revenue diversification analysis shows BMY's business is primarily driven by Eliquis (30%), Opdivo (21%), and Orencia (8%).
When compared to Healthcare sector peers including PFE (+1.4% YoY), MRK (+1.2% YoY), and ABBV (+8.6% YoY), BMY has underperformed the peer group in terms of revenue growth. Compare BMY vs PFE →
BMY Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BMYCurrent | $48.5B | +2.6% | +2.5% | 26.3% | |
 PFE | $62.6B | +1.4% | +8.5% | 24.7% | |
 MRK | $64.9B | +1.2% | +9.4% | 36.2% | |
 ABBV | $61.2B | +8.6% | +6.0% | 32.8% | |
 LLY | $65.2B | +47.4% | +21.6% | 45.6% | |
 JNJ | $88.8B | +3.7% | +1.6% | 24.9% |
BMY Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $48.19B | -0.2% | $32.60B | 67.6% | $12.70B | 26.3% |
| 2024 | $48.30B | +7.3% | $27.43B | 56.8% | $9.66B | 20.0% |
| 2023 | $45.01B | -2.5% | $25.36B | 56.3% | $8.47B | 18.8% |
| 2022 | $46.16B | -0.5% | $26.49B | 57.4% | $9.27B | 20.1% |
| 2021 | $46.38B | +9.1% | $26.76B | 57.7% | $9.54B | 20.6% |
| 2020 | $42.52B | +62.6% | $21.70B | 51.0% | $4.49B | 10.6% |
| 2019 | $26.14B | +15.9% | $17.25B | 66.0% | $6.44B | 24.6% |
| 2018 | $22.56B | +8.6% | $16.07B | 71.3% | $6.39B | 28.3% |
| 2017 | $20.78B | +6.9% | $14.96B | 72.0% | $5.24B | 25.2% |
| 2016 | $19.43B | +17.3% | $14.49B | 74.6% | $5.18B | 26.7% |
Full BMY Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See BMY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BMY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BMY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBMY — Frequently Asked Questions
Quick answers to the most common questions about buying BMY stock.
Is BMY's revenue growth accelerating or slowing?
BMY revenue growth slowed to +2.6%, below the 5-year CAGR of +2.5%. TTM revenue is $48.5B. The deceleration marks a shift from historical growth rates.
What is BMY's long-term revenue growth rate?
Bristol-Myers Squibb Company's 5-year revenue CAGR of +2.5% reflects the variable expansion pattern. Current YoY growth of +2.6% is near this long-term average.
How is BMY's revenue distributed by segment?
BMY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.